Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893961175> ?p ?o ?g. }
- W2893961175 endingPage "144" @default.
- W2893961175 startingPage "136" @default.
- W2893961175 abstract "Purpose To evaluate the efficacy, safety, and quality of life (QOL) of transdermal androgen in treatment of dry eye patients associated with androgen deficiency. Design Randomized controlled trial. Methods Fifty patients with dry eye from a tertiary eye center in northern Thailand were randomized to receive transdermal androgen (AndroGel; Besins Healthcare, Brussels, Belgium) or placebo for 4 weeks. Main outcome measures were symptoms and signs of dry eye. Serum level of sex hormone and QOL questionnaires were also evaluated at the baseline and after treatment. Results After 4 weeks, the Ocular Surface Disease Index decreased significantly in the AndroGel group compared to the placebo (−14.36 ± 7.76 vs 0.14 ± 14.60, P < .001). Significant improvements of tear break-up time (7.40 ± 3.37 vs −1.14 ± 1.68 seconds, P < .001), corneal fluorescein staining (−0.62 ± 0.30 vs 0.19 ± 0.37, P < .001), and Schirmer test (6.84 ± 5.10 vs −0.48 ± 2.14 mm, P < .001) were observed in the AndroGel group compared to the placebo. Serum testosterone in female patients significantly increased in the AndroGel group compared to the placebo (P < .001), while no different change was observed in serum testosterone in male subjects and the sex hormone-binding globulin in both groups. In the AndroGel group, 20% of patients had oily skin and 4% had acne. No serious adverse effects were reported. The menopause rating score improved significantly in the AndroGel group compared to the placebo (P < .001), while the aging male symptoms were not different in both groups (P = .589). Conclusions Transdermal androgen was effective in relieving symptoms and signs of dry eye as well as improving QOL in aging patients. There were no serious side effects during a short-term treatment. To evaluate the efficacy, safety, and quality of life (QOL) of transdermal androgen in treatment of dry eye patients associated with androgen deficiency. Randomized controlled trial. Fifty patients with dry eye from a tertiary eye center in northern Thailand were randomized to receive transdermal androgen (AndroGel; Besins Healthcare, Brussels, Belgium) or placebo for 4 weeks. Main outcome measures were symptoms and signs of dry eye. Serum level of sex hormone and QOL questionnaires were also evaluated at the baseline and after treatment. After 4 weeks, the Ocular Surface Disease Index decreased significantly in the AndroGel group compared to the placebo (−14.36 ± 7.76 vs 0.14 ± 14.60, P < .001). Significant improvements of tear break-up time (7.40 ± 3.37 vs −1.14 ± 1.68 seconds, P < .001), corneal fluorescein staining (−0.62 ± 0.30 vs 0.19 ± 0.37, P < .001), and Schirmer test (6.84 ± 5.10 vs −0.48 ± 2.14 mm, P < .001) were observed in the AndroGel group compared to the placebo. Serum testosterone in female patients significantly increased in the AndroGel group compared to the placebo (P < .001), while no different change was observed in serum testosterone in male subjects and the sex hormone-binding globulin in both groups. In the AndroGel group, 20% of patients had oily skin and 4% had acne. No serious adverse effects were reported. The menopause rating score improved significantly in the AndroGel group compared to the placebo (P < .001), while the aging male symptoms were not different in both groups (P = .589). Transdermal androgen was effective in relieving symptoms and signs of dry eye as well as improving QOL in aging patients. There were no serious side effects during a short-term treatment." @default.
- W2893961175 created "2018-10-05" @default.
- W2893961175 creator A5010120544 @default.
- W2893961175 creator A5031510535 @default.
- W2893961175 creator A5044586801 @default.
- W2893961175 creator A5066220415 @default.
- W2893961175 creator A5085277808 @default.
- W2893961175 date "2019-01-01" @default.
- W2893961175 modified "2023-09-24" @default.
- W2893961175 title "A Randomized Controlled Double-Masked Study of Transdermal Androgen in Dry Eye Patients Associated With Androgen Deficiency" @default.
- W2893961175 cites W1485401844 @default.
- W2893961175 cites W1824111805 @default.
- W2893961175 cites W1963558638 @default.
- W2893961175 cites W1963970745 @default.
- W2893961175 cites W1977161781 @default.
- W2893961175 cites W1998270868 @default.
- W2893961175 cites W2013281526 @default.
- W2893961175 cites W2021443932 @default.
- W2893961175 cites W2027853781 @default.
- W2893961175 cites W2054413572 @default.
- W2893961175 cites W2055805284 @default.
- W2893961175 cites W2064496002 @default.
- W2893961175 cites W2064859777 @default.
- W2893961175 cites W2066210489 @default.
- W2893961175 cites W2080839328 @default.
- W2893961175 cites W2143619267 @default.
- W2893961175 cites W2151640822 @default.
- W2893961175 cites W2161057551 @default.
- W2893961175 cites W2168495930 @default.
- W2893961175 cites W2547357227 @default.
- W2893961175 cites W2580634790 @default.
- W2893961175 cites W2737787547 @default.
- W2893961175 cites W2738627012 @default.
- W2893961175 cites W2739359388 @default.
- W2893961175 cites W2898050329 @default.
- W2893961175 cites W4246234200 @default.
- W2893961175 doi "https://doi.org/10.1016/j.ajo.2018.09.021" @default.
- W2893961175 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30268865" @default.
- W2893961175 hasPublicationYear "2019" @default.
- W2893961175 type Work @default.
- W2893961175 sameAs 2893961175 @default.
- W2893961175 citedByCount "5" @default.
- W2893961175 countsByYear W28939611752020 @default.
- W2893961175 countsByYear W28939611752022 @default.
- W2893961175 countsByYear W28939611752023 @default.
- W2893961175 crossrefType "journal-article" @default.
- W2893961175 hasAuthorship W2893961175A5010120544 @default.
- W2893961175 hasAuthorship W2893961175A5031510535 @default.
- W2893961175 hasAuthorship W2893961175A5044586801 @default.
- W2893961175 hasAuthorship W2893961175A5066220415 @default.
- W2893961175 hasAuthorship W2893961175A5085277808 @default.
- W2893961175 hasConcept C126322002 @default.
- W2893961175 hasConcept C134018914 @default.
- W2893961175 hasConcept C142724271 @default.
- W2893961175 hasConcept C168563851 @default.
- W2893961175 hasConcept C197934379 @default.
- W2893961175 hasConcept C204243189 @default.
- W2893961175 hasConcept C204787440 @default.
- W2893961175 hasConcept C205679159 @default.
- W2893961175 hasConcept C27081682 @default.
- W2893961175 hasConcept C2777911890 @default.
- W2893961175 hasConcept C2778562196 @default.
- W2893961175 hasConcept C2779279991 @default.
- W2893961175 hasConcept C2779665388 @default.
- W2893961175 hasConcept C71315377 @default.
- W2893961175 hasConcept C71924100 @default.
- W2893961175 hasConcept C90924648 @default.
- W2893961175 hasConcept C98274493 @default.
- W2893961175 hasConceptScore W2893961175C126322002 @default.
- W2893961175 hasConceptScore W2893961175C134018914 @default.
- W2893961175 hasConceptScore W2893961175C142724271 @default.
- W2893961175 hasConceptScore W2893961175C168563851 @default.
- W2893961175 hasConceptScore W2893961175C197934379 @default.
- W2893961175 hasConceptScore W2893961175C204243189 @default.
- W2893961175 hasConceptScore W2893961175C204787440 @default.
- W2893961175 hasConceptScore W2893961175C205679159 @default.
- W2893961175 hasConceptScore W2893961175C27081682 @default.
- W2893961175 hasConceptScore W2893961175C2777911890 @default.
- W2893961175 hasConceptScore W2893961175C2778562196 @default.
- W2893961175 hasConceptScore W2893961175C2779279991 @default.
- W2893961175 hasConceptScore W2893961175C2779665388 @default.
- W2893961175 hasConceptScore W2893961175C71315377 @default.
- W2893961175 hasConceptScore W2893961175C71924100 @default.
- W2893961175 hasConceptScore W2893961175C90924648 @default.
- W2893961175 hasConceptScore W2893961175C98274493 @default.
- W2893961175 hasFunder F4320335535 @default.
- W2893961175 hasLocation W28939611751 @default.
- W2893961175 hasLocation W28939611752 @default.
- W2893961175 hasOpenAccess W2893961175 @default.
- W2893961175 hasPrimaryLocation W28939611751 @default.
- W2893961175 hasRelatedWork W1979452793 @default.
- W2893961175 hasRelatedWork W1981433740 @default.
- W2893961175 hasRelatedWork W1986311037 @default.
- W2893961175 hasRelatedWork W1986969712 @default.
- W2893961175 hasRelatedWork W2023030003 @default.
- W2893961175 hasRelatedWork W2024718203 @default.
- W2893961175 hasRelatedWork W2030888955 @default.
- W2893961175 hasRelatedWork W2061554880 @default.